Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant

Clinical Transplantation

Volumn 24, Issue 6, 2010, Pages 821-829

  Domingues, Elizabeth M F L ^a   Matuck, Teresa ^b   Graciano, Miguel L ^b   Souza, Edison ^c   Rioja, Suzimar ^c   Falci, Mônica C ^a   Monteiro De Carvalho, Deise B ^b   Pôrto, Luís Cristóvão ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL GERAL DE BONSUCESSO   (Brazil)

^c HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Acute rejection; CD30; Kidney; Panel reactive antibodies; Transplant

Indexed keywords

CD30 ANTIGEN; HLA ANTIBODY; PANEL REACTIVE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HLA MATCHING; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTIGENS, CD30; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; RISK FACTORS; SURVIVAL RATE;

EID: 78649953301     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01182.x     Document Type: Article

References (45)

1. Mihaylova A, Baltadjieva D, Boneva P et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays - single-center experience. Hum Immunol 2006: 67: 787.
2. Kaufman A, De Souza Pontes LF, Queiroz Marques MT, Sampaio JC, De Moraes Sobrino Porto LC, De Moraes Souza ER. Analysis of AHG-PRA and ELISA-PRA in kidney transplant patients with acute rejection episodes. Transpl Immunol 2003: 11: 175.
3. Van Der Mast BJ, Van Besouw NM, Witvliet MD et al. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression. Transplantation 2003: 75: 871.
4. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002: 11: 609.
5. Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005: 79: 591.
6. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003: 63: 1888.
7. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982: 299: 65.
8. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003: 10: 267.
9. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998: 10: 457.
10. Hansen HP, Dietrich S, Kisseleva T et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000: 165: 6703.
11. Del Prete G, De Carli M, D'Elios MM et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995: 182: 1655.
12. Ansieau S, Scheffrahn I, Mosialos G et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996: 93: 14053.
13. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003: 12: 49.
14. Susal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003: 76: 1231.
15. Susal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004: 36: 29.
16. Slavcev A, Lacha J, Honsova E et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005: 14: 117.
17. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
18. Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007: 7: 1743.
19. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004: 4: 438.
20. Martins L, Fonseca I, Sousa S et al. The influence of HLA mismatches and immunosuppression on kidney graft survival: an analysis of more than 1300 patients. Transplant Proc 2007: 39: 2489.
21. Langan LL, Park LP, Hughes TL et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007: 7: 847.
22. Slavcev A, Lacha J, Sajdlova H et al. Antibodies to HLA class II antigens as a risk factor for acute rejection of the allogeneic kidney. Ann Transplant 2004: 9: 44.
23. Lieber SR, Perez FV, Tabossi MR et al. Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients. Transplant Proc 2007: 39: 429.
24. Adeyi OA, Girnita AL, Howe J et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005: 14: 53.
25. Mizutani K, Terasaki PI, Shih RN, Pei R, Ozawa M, Lee J. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol 2006: 67: 223.
26. Hankey KG, Drachenberg CB, Papadimitriou JC et al. MIC expression in renal and pancreatic allografts. Transplantation 2002: 73: 304.
27. Mizutani K, Terasaki P, Rosen A et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005: 5: 2265.
28. Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006: 67: 230.
29. Martinez OM, Villanueva J, Abtahi S, Beatty PR, Esquivel CO, Krams SM. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998: 65: 1240.
30. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002: 13: 1650.
31. Pelzl S, Opelz G, Daniel V, Wiesel M, Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003: 75: 421.
32. Cinti P, Pretagostini R, Arpino A et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005: 79: 1154.
33. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002: 73: 3.
34. Dong W, Shunliang Y, Weizhen W et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006: 16: 41.
35. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002: 73: 1269.
36. Slavcev A, Honsova E, Lodererova A et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 2007: 18: 22.
37. Rajakariar R, Jivanji N, Varagunam M et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005: 5: 1922.
38. Bohmig G, Regele H. Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transpl Int 2003: 16: 773.
39. Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001: 16: 2058.
40. Jianghua C, Wenqing X, Huiping W, Juan J, Jianyong W, Qiang H. C4d as a significant predictor for humoral rejection in renal allografts. Clin Transplant 2005: 19: 785.
41. Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004: 4: 124.
42. Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004: 65: 2409.
43. Rodriguez LM, Paris SC, Arbelaez M et al. Kidney graft recipients with pretransplantation HLA Class I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007: 68: 652.
44. Vaidya S, Partlow D, Barnes T, Gugliuzza K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006: 82: 1606.
45. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007: 83: 398.